Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia.

Fung SJ, Webster MJ, Sivagnanasundaram S, Duncan C, Elashoff M, Weickert CS.

Am J Psychiatry. 2010 Dec;167(12):1479-88. doi: 10.1176/appi.ajp.2010.09060784.

PMID:
21041246
2.
3.

Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia.

Volk DW, Lewis DA.

Neuroscience. 2013 Sep 17;248:154-64. doi: 10.1016/j.neuroscience.2013.06.008. Review.

4.

Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia.

Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU.

Biol Psychiatry. 1999 Sep 1;46(5):616-26. Review.

PMID:
10472415
5.

Early developmental disturbances of cortical inhibitory neurons: contribution to cognitive deficits in schizophrenia.

Volk DW, Lewis DA.

Schizophr Bull. 2014 Sep;40(5):952-7. doi: 10.1093/schbul/sbu111. Review.

6.

Postnatal development of calcium-binding proteins immunoreactivity (parvalbumin, calbindin, calretinin) in the human entorhinal cortex.

Grateron L, Cebada-Sanchez S, Marcos P, Mohedano-Moriano A, Insausti AM, Muñoz M, Arroyo-Jimenez MM, Martinez-Marcos A, Artacho-Perula E, Blaizot X, Insausti R.

J Chem Neuroanat. 2003 Dec;26(4):311-6. Review.

PMID:
14729133
7.

Neuronal calcium-binding proteins and schizophrenia.

Eyles DW, McGrath JJ, Reynolds GP.

Schizophr Res. 2002 Sep 1;57(1):27-34. Review.

PMID:
12165373
8.
9.

Layer 3 Excitatory and Inhibitory Circuitry in the Prefrontal Cortex: Developmental Trajectories and Alterations in Schizophrenia.

Hoftman GD, Datta D, Lewis DA.

Biol Psychiatry. 2016 Jun 4. pii: S0006-3223(16)32427-1. doi: 10.1016/j.biopsych.2016.05.022. [Epub ahead of print] Review.

PMID:
27455897
10.

Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models.

O'Donnell P.

Schizophr Bull. 2011 May;37(3):484-92. doi: 10.1093/schbul/sbr028. Review.

11.

Cell-based therapies for the treatment of schizophrenia.

Donegan JJ, Lodge DJ.

Brain Res. 2017 Jan 15;1655:262-269. doi: 10.1016/j.brainres.2016.08.010. Review.

PMID:
27544423
12.

GABAergic Function as a Limiting Factor for Prefrontal Maturation during Adolescence.

Caballero A, Tseng KY.

Trends Neurosci. 2016 Jul;39(7):441-8. doi: 10.1016/j.tins.2016.04.010. Review.

PMID:
27233681
13.

Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.

Do KQ, Cuenod M, Hensch TK.

Schizophr Bull. 2015 Jul;41(4):835-46. doi: 10.1093/schbul/sbv065. Review.

14.

Immune system disturbances in schizophrenia.

Horváth S, Mirnics K.

Biol Psychiatry. 2014 Feb 15;75(4):316-23. doi: 10.1016/j.biopsych.2013.06.010. Review.

15.

Early rescue of interneuron disease trajectory in developmental epilepsies.

Siehr MS, Noebels JL.

Curr Opin Neurobiol. 2016 Feb;36:82-8. doi: 10.1016/j.conb.2015.10.007. Review.

16.

Interneuron dysfunction in psychiatric disorders.

Marín O.

Nat Rev Neurosci. 2012 Jan 18;13(2):107-20. doi: 10.1038/nrn3155. Review.

PMID:
22251963
17.

Different Paths to Core Pathology: The Equifinal Model of the Schizophrenia Syndrome.

Green IW, Glausier JR.

Schizophr Bull. 2016 May;42(3):542-9. doi: 10.1093/schbul/sbv136. Review.

PMID:
26392629

Supplemental Content

Support Center